Condition: Ventricular Tachycardia · Ventricular Arrhythmias · Ventricular Fibrillation · Sponsor: Ottawa Heart Institute Research Corporation
The objective of this study is to determine if there is a meaningful benefit to using the sedative medication dexmedetomidine in the acute treatment of patients with recurrent ventricular arrhythmias, known as electrical storm. This will be a multi-centre, double-blinded, placebo-controlled, randomized trial. Patients with electrical storm will be randomized to receive 48 to 72 hours of dexmedetomidine or placebo as part of their initial treatment in an intensive care unit.
This description comes directly from the study's public registry record.
F. Daniel Ramirez, MD MSc · 613-696-7402 · dramirez@ottawaheart.ca
Benjamin Hibbert, MD PhD · hibbert.benjamin@mayo.edu
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Rochester, Minnesota, United States | Not Yet Recruiting |
| University of Ottawa Heart Institute | Ottawa, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06281977